Micronoma - Micronoma

MICROBIOME DRIVEN LIQUID BIOPSY™

We are focused on developing the first minimally invasive microbiome-driven liquid biopsy laboratory-developed test (LDT) that uses microbial nucleic acid to help diagnose cancer at an early stage.

REDEFINING EARLY STAGE DETECTION WITH ONCOBIOTA™

Our Oncobiota™ platform technology is designed to detect cancer in early stages (I and II), utilizing pioneering microbial research, next gen sequencing and AI, with great sensitivity and specificity.

ONE CANCER AT A TIME, STARTING WITH LUNG

We are dedicated to bringing advanced diagnostic services to physicians one cancer at a time. By adding targeted tools to the physician toolkit, we are dedicated to achieving actionable results that can lead to cost savings and more lives saved. Learn more here.

“There are more microbes in the human body than there are stars in the galaxy. With this much information to tackle, we are converging advances in the understanding of cancer, microbiome, molecular technologies, and big data science into new, exciting capabilities to diagnose disease early and save lives. We have a line of sight on powerful new solutions that we believe could revolutionize the standard of care.”

Sandrine Miller-Montgomery, CEO & Co-Founder of Micronoma

THE PROBLEM

MILLION

New cancer cases
worldwide each year

MILLION

Cancer deaths each year

MILLION

Deaths each year could be prevented with early detection

Sung, H. et. al.(2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 71(3), 209–249.

Solution:

Oncobiota^TM

The diagnostic implications of microbiome markers in tissue and liquid biopsies are endless. As the only cancer diagnostic company that is developing a diagnostic platform technology using the microbiome to detect early-stage cancer, Micronoma has the cutting-edge advantage.

Our patent pending Oncobiota™ platform is designed to reveal cancer-related microbiome with high specificity and sensitivity. We are actively developing a minimally invasive and precise microbiome-driven liquid biopsy™ laboratory-developed test (LDT) for detecting cancer in its earliest stages, unlike tests that only focus on the human genome, epigenome, or cancer mutations.

Oncobiota™ has the potential to be applied to many cancer types. Starting with lung cancer, which has the highest need for early detection in terms of incidence and mortality rates, we believe our innovative LDT technology can make a big difference in the lives of the many patients affected by cancer each year.

Learn More

Potential Advantages Over Traditional Liquid Biopsy

A genetic sequencing-based liquid biopsy usually refers to a test done on a sample of blood to look for one or more genetic biomarker(s) associated with a cancer, such as methylation or fragmentation profile of genetic materials isolated from circulating tumor cells (CTC) and/or cell-free DNA that is shed from the tumor.

___________

However, these types of genetic biomarkers are more easily detected for large tumors, which makes such methods less efficient for detecting cancer at its earliest stages.*

___________

At Micronoma, we focus on the circulating microbial nucleic acid signatures, or microbiome biomarkers, that are associated with the tumor and the body’s response to the developing tumor. Importantly, and based on published data, these microbial signals do not seem to be dependent on tumor size, potentially enabling our proprietary platform to detect cancer at an earlier stage of cancer development.

*Avanzini, S. et.al. (2020). A mathematical model of ctDNA shedding predicts tumor detection size. Science advances, 6(50), eabc4308. https://doi.org/10.1126/sciadv.abc4308

Our novel proprietary method for detecting specific microbiome biomarkers in a simple blood draw is designed to offer a revolutionary new option for early cancer detection.”

Rob Knight, PhD, Co-Founder of Micronoma

Humans and Microbes

Humans and microbes co-exist in a mutually beneficial relationship in our bodies. Microbes can be found naturally not only in our stools, but also in our mouths, tissues, and blood, even when we are healthy.

The Microbiome

The microbiome is the community of all the microbes—bacteria, fungi, protozoa, and viruses—that live on and inside the human body. The composition of the microbiome changes with many factors such as location in the body, lifestyle, and gender. If analyzed properly, the microbiome can reveal the status of our health.

Microbes and Cancer

Microbes are now known to be found in human tissues, including cancer tissues and blood. Micronoma’s proprietary platform and global expertise allow for the development of innovative LDTs for identification of microbial signatures in circulating blood that are predictive of a cancerous tumor. This type of minimally invasive liquid biopsy LDT uses blood samples, which can be more easily collected than solid tissue samples.

Latest News

Special Report: Life Science, Merging the Biological With the Computational

When scientists began mapping of the human genome, the discoveries in our DNA unleashed an era of biology that advanced breakthroughs in diagnostics and biomedicine beyond what was imaginable when the work began. Today, with DNA sequencers readily available in many...